Citigroup Downgrades Moderna to Sell, Raises Price Target to $80

Benzinga Newsdesk www.benzinga.com Neutral 43.6%

Neg 0% Neu 43.6% Pos 0%

Citigroup analyst Geoff Meacham downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $60 to $80.